This article is among the few that hit today about GlaxoSmithKline (GSK) being given priority status by the FDA. Basically this means the process of approval for this drug will be expedited . The drug, Dolutegravir is being developed as a means to combat HIV in patients who have developed resistance to Raltegravir.
This is great & all, but that didn't seem to be the point of any the articles I readr. The articles all seemed to focus on $. This drug would better equip GSK to to do monetary battle with Gilead. I know $ is important, but it would seem the idea of new medicine to fight HIV could take precedence at least for a little while.
Just my thoughts on the matter.
Cya....
No comments:
Post a Comment